Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU). Sixteen patients had received prior systemic therapy, and 16 had visceral involvement. There were no objective regressions among ten patients receiving the drugs as initial systemic therapy. However, one of 16 patients having prior systemic treatment did have an objective response. Hematologic and gastrointestinal toxic effects were well-tolerated.
D000368:Aged; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage* / Q000009:adverse effects; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D010865:Pilot Projects; D010976:Platelet Count; D012673:Semustine / Q000008:administration & dosage* / Q000009:adverse effects; D012878:Skin Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D009607:Nitrosourea Compounds; D012673:Semustine; D008936:Mitolactol